4-Aminotetrahydropyran → HCID 49793134, 화합물
반응식
CO[C:3]([C:5]1[N:6]([CH3:26])[N:7]=[C:8]([O:10][CH2:11][C:12]2[C:13]([C:19]3[CH:24]=[CH:23][C:22]([F:25])=[CH:21][CH:20]=3)=[N:14][O:15][C:16]=2[CH2:17][OH:18])[CH:9]=1)=[O:4].COC(C1NN=C(OC[C:38]2[C:39]([C:44]3[CH:49]=CC=CC=3)=[N:40][O:41][C:42]=2C)C=1)=O.NC1CCOCC1>>[O:41]1[CH2:49][CH2:44][CH:39]([NH:40][C:3]([C:5]2[N:6]([CH3:26])[N:7]=[C:8]([O:10][CH2:11][C:12]3[C:13]([C:19]4[CH:20]=[CH:21][C:22]([F:25])=[CH:23][CH:24]=4)=[N:14][O:15][C:16]=3[CH2:17][OH:18])[CH:9]=2)=[O:4])[CH2:38][CH2:42]1참가 물질
4
실험 절차
As described for example 1b, 5-[3-(4-fluoro-phenyl)-5-hydroxymethyl-isoxazol-4-ylmethoxy]-2-methyl-2H-pyrazole-3-carboxylic acid methyl ester (150 mg, 0.42 mmol), instead of 5-(5-methyl-3-phenyl-isoxazol-4-ylmethoxy)-2H-pyrazole-3-carboxylic acid methyl ester, was converted, using 4-aminotetrahydropyran instead of morpholine, to the title compound (120 mg, 67%) which was obtained as a white solid. MS: m/e=429.1 [M−H]−.